spacer
home > ebr > > robotics in pharmaceutical research
PUBLICATIONS
European Biopharmaceutical Review

Robotics in Pharmaceutical Research

'Robot' is a Czech word meaning worker, from the play RUR: Rossums' Universal Robots by the Bohemian writer Karel Capek. The robot has since become an inspiration for science fiction writers and for engineers. Of course the science fiction vision of a robot is a mechanical man, but the reality we see in industry is simply a robotic arm. This is a versatile programmable manipulator, an integration of mechanics, electronics and software, designed interdependently to produce the mechanical equivalent of the computer - an undedicated machine unable to do anything until we program it.

In the pharmaceutical lab it is even less than that definition; the term 'robot' being applied to programmable liquid handlers. Drug development requires the screening of hundreds or thousands of samples and it is in this field that the robot arm is a vital tool. Such an automated screening system is called a 'high-throughput screening' (HTS) system.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
5
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By David N Sands, CEO and Founder of ST Robotics International

David N Sands was educated in London. He founded Sands-Whiteley Research and Development, which concentrated on advanced electronics and industrial automation using mini-computers and later microprocessors. David was a Department of Industry Consultant on microprocessors for many years. In 1982 the first robots were designed and Cyber Robotics, which was later sold to the Bibby Corporation, was formed the same year.

David wrote the first robot software, ROBOFORTH, in 1982 and designed the first robot controller in 1985. In 1989 he formed Sands Technology with Catherine George and ST-Monforte Robotics with Mathew Monforte in Trenton, New Jersey, in 1991. Sands Technology International Inc was formed in 1992 with Mathew Monforte as Vice President.
 

spacer
David N Sands
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioBLU® family grows

Juelich/Hannover, October 14th, 2013 – At this year’s BIOTECHNICA in Hannover, Germany Eppendorf has presented the newest members of its single-use bioreactor family BioBLU for the first time. With the new single-use bioreactor BioBLU 1c for cell culture and BioBLU 1f for microbial applications Eppendorf further extends its portfolio of rigid wall single-use bioreactors. These 1 L vessels are bridging the gap between the BioBLU 0.3 c/f mini single-use bioreactors and the larger vessels of the BioBLU family. Users in cell culture, who want to combine the advantages of single-use technology with the proven qualities of stirred-tank bioreactor design can now benefit from an unmatched portfolio of rigid wall stirred tank single-use bioreactors with working volumes from 100 mL – 40 L.
More info >>

White Papers

The Power of Execution in Clinical Research

Medpace

Medpace, long known for its excellence in conducting Phase I-IV studies on a global platform, is particularly noted for its therapeutic excellence. When that expertise is combined with operational precision, the results are nothing short of stellar. The Medpace full-service outsourcing approach – combined with therapeutic expertise, regulatory know how, and global presence – delivers clinical studies with an industry recognized track record.
More info >>

 
Industry Events

Advances in Cancer Immunotherapies 2014 (ACI2014)

15-16 October 2014, Singapore

Approximately 12.5 million new cases of cancer are being diagnosed worldwide each year, making cancer a new global pandemic with huge economic impact on the healthcare industry.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement